Atreca Stock News

Atreca Inc - Class A (BCEL) shares closed today at 1.1% above its 52 week low of $2.85, giving the company a market cap of $87M. The stock is currently down 5.0% year-to-date, down 81.7% over the past 12 months, and down 84.0% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 0.1%. Trading Activity Trading volume this week was 13.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -266.0% The company's stock price performance over the past 12 months lags the peer average by 173.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique

SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d

Gainers Del Taco Restaurants, Inc. (NASDAQ: TACO ) shares jumped 64.6% to $12.40. Jack In The Box Inc (NASDAQ: JACK ) agreed to acquire Del Taco Restaurants for $12.51 per share in cash in a deal valued at about $575 million. BuzzFeed (NASDAQ: BZFD) surged 37.2% to $13.20. The company has called itself "the first publicly traded purely digital media company." Buzzfeed started trading on the Nasdaq today. Insignia Systems, Inc. (NASDAQ: ISIG ) gained 31.5% to $6.59 after the company reported review of strategic alternatives. Adicet Bio, Inc. (NASDAQ: ACET ) shares climbed 28.2% to $12.56 after the company announced interim data from its dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001. Cloopen Group Holding Limited (NYSE: RAAS ) gained 23% to $3.3174. Sunlands Technology Group (NYSE: STG ) jumped 18.2% to $3.7850. Sunlands Technology announced that its Board has approved a share repurchase program to repurchase up to $15 million of its Class A ordinary shares.

Goldman Sachs Group Inc. cut its stake in shares of Atreca, Inc. (NASDAQ:BCEL) by 63.0% in the 2nd quarter, Holdings Channel reports. The fund owned 99,913 shares of the companys stock after selling 170,340 shares during the quarter. Goldman Sachs Group Inc.s holdings in Atreca were worth $851,000 as of its most recent filing with []

Atreca Inc. (NASDAQ:BCEL) has seen 1.87 million shares traded in the last trading session. The company, currently valued at $134.16M, closed the last trade at $3.59 per share which meant it lost -$0.36 on the day or -9.11% during that session. The BCEL stock price is -465.18% off its 52-week high price of $20.29 and Atreca Inc. (BCEL): What Is Good About Stock? Read More »

State Street Corp reduced its position in shares of Atreca, Inc. (NASDAQ:BCEL) by 56.4% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 491,632 shares of the companys stock after selling 634,868 shares during the quarter. State Street Corp owned 1.33% of Atreca worth []

Brokerages expect that Atreca, Inc. (NASDAQ:BCEL) will announce ($0.75) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Atrecas earnings, with estimates ranging from ($0.83) to ($0.69). Atreca reported earnings of ($0.63) per share in the same quarter last year, which would suggest a negative year-over-year []

Geode Capital Management LLC decreased its position in shares of Atreca, Inc. (NASDAQ:BCEL) by 1.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 449,553 shares of the companys stock after selling 5,659 shares during the quarter. Geode Capital Management LLCs holdings in Atreca []

Atreca announced preliminary results using ATRC-101 in a phase 1b study treating patients with advanced solid tumors. One expansion cohort will include the combination of ATRC-101 and Keytruda which a

SAN CARLOS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d

SAN CARLOS, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d

BCEL has very high smart money involvement. Poor adverse event data brought the stock down in July.

SAN CARLOS, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique

SAN CARLOS, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d